Application 125476

Type
BLA
Sponsor
TAKEDA PHARMS USA

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001ENTYVIOVEDOLIZUMABINJECTABLE;INJECTION300MGNoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent
64764-300EntyviovedolizumabTakeda Pharmaceuticals America, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
85184SUPPL 2026-03-02
85171SUPPL 2026-02-27
78403SUPPL 2024-05-06
78402SUPPL 2024-05-06
78177SUPPL 2024-04-19
78176SUPPL 2024-04-19
77845SUPPL 2024-03-15
77839SUPPL 2024-03-15
77838SUPPL 2024-03-15
77627SUPPL 2024-02-26
77616SUPPL 2024-02-26
75625SUPPL 2023-09-29
75614SUPPL 2023-09-29
71418SUPPL2022-06-21
71372SUPPL2022-06-21
68415SUPPL2021-08-19
68414SUPPL2021-08-19
68401SUPPL2021-08-18
68400SUPPL2021-08-18
62418SUPPL2020-04-02
62417SUPPL2020-04-02
62404SUPPL2020-04-01
62403SUPPL2020-04-01
62402SUPPL2020-04-01
62401SUPPL2020-04-01
58641SUPPL2019-05-13
58617SUPPL2019-05-08
58616SUPPL2019-05-08
52701SUPPL2018-02-23
52684SUPPL2018-02-22
52683SUPPL2018-02-22
24373ORIG2014-06-19
22814ORIG2014-06-19
39973ORIG2014-05-20
9765ORIG2014-05-20